Arcotatug
Based on 1 Customer Validation
Arcotatug (IBI-343 antibody) is a CLDN18.2 targeting humanized monoclonal antibody. Arcotatug can be used for synthesis of ADCs.
For research use only. We do not sell to patients.
- Purity : 98%
- CAS No.: 3031170-61-0
- Molecular Weight:145.647 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
CLDN18.2 |
In Vitro
Arcotatug can be used to synthesize ADC Arcotatug tavatecan (IBI343), which shows anticancer activity in gastric or gastroesophageal junction adenocarcinoma[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 3031170-61-0
-
Appearance Liquid
-
Molecular Weight 145.647 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Synonyms
IBI-343 antibody; HB37A6; TAK-921 Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Arcotatug
- 3031170-61-0
- IBI-343 antibody
- HB37A6
- TAK-921 Antibody
- ADC Antibodies
- Claudin
- antibody-dependent cellular cytotoxicity
- complement-dependent cytotoxicity
- CLDN18.2
- IgG1 Fc silencing
- pancreatic ductal adenocarcinoma
- topoisomerase I
- gastric adenocarcinoma
- gastroesophageal junction adenocarcinoma
- biliary tract cancer
- Inhibitor
- inhibitor
- inhibit